Patents matching “anti-”

US 9968674

Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody

REGENERON PHARMACEUTICALS, INC. · Granted May 15, 2018 · Expires May 10, 2038

US 9963515

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted May 8, 2018 · Expires May 3, 2038

US 9963504

Anti-CXCL13 antibodies and methods of using the same

VACCINEX, INC. · Granted May 8, 2018 · Expires May 3, 2038

US 9957305

Anti-C. difficile toxin antibodies and associated methods

The Board of Regents of the University of Oklahoma · Granted May 1, 2018 · Expires Apr 26, 2038

US 9957324

Anti-FLT-1 antibodies in treating duchenne muscular dystrophy

Regents of the University of Minnesota · Granted May 1, 2018 · Expires Apr 26, 2038

US 9951311

Agents and methods to elicit anti-tumor immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 24, 2018 · Expires Apr 19, 2038

US 9951132

Anti-prokineticin receptor (PROKR) antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Apr 24, 2018 · Expires Apr 19, 2038

US 9951127

Anti-ANGPTL3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Apr 24, 2018 · Expires Apr 19, 2038

US 9937159

Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs

Lutonix, Inc. · Granted Apr 10, 2018 · Expires Apr 5, 2038

US 9925180

Compounds and anti-tumor NQO1 substrates

The Board of Regents of the University of Texas System · Granted Mar 27, 2018 · Expires Mar 22, 2038

US 9926369

Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Mar 27, 2018 · Expires Mar 22, 2038

US 9919056

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA · Granted Mar 20, 2018 · Expires Mar 15, 2038

US 9913900

Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 13, 2018 · Expires Mar 8, 2038

US 9913822

Combination therapy with an anti-hyaluronan agent and therapeutic agent

HALOZYME, INC. · Granted Mar 13, 2018 · Expires Mar 8, 2038

US 9914773

Anti-human folate receptor beta antibodies and methods of use

THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Mar 13, 2018 · Expires Mar 8, 2038

US 9884009

Plant composition having moisturizing, anti-wrinkle, and anti-allergic efficacies, and preparation method thereof

INFINITUS (CHINA) COMPANY LTD. · Granted Feb 6, 2018 · Expires Feb 1, 2038

US 9878046

Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects

HALOZYME, INC. · Granted Jan 30, 2018 · Expires Jan 25, 2038

US 9878984

Anti-cancer compounds

Northwestern University · Granted Jan 30, 2018 · Expires Jan 25, 2038

US 9868961

Methods and compositions for localized secretion of anti-CTLA-4 antibodies

The Regents of the University of California · Granted Jan 16, 2018 · Expires Jan 11, 2038

US 9868774

Anti-CD22 chimeric antigen receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 16, 2018 · Expires Jan 11, 2038

US 9855291

Anti-kidney associated antigen 1 (KAAG1) antibodies

ADC THERAPEUTICS SA · Granted Jan 2, 2018 · Expires Dec 28, 2037

US 9840559

Anti-CD83 antibodies and use thereof

The Regents of the University of California · Granted Dec 12, 2017 · Expires Dec 7, 2037

US 9840557

Anti-IL-25 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Dec 12, 2017 · Expires Dec 7, 2037

US 9833427

Creatine ester anti-inflammatory compounds and formulations

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Dec 5, 2017 · Expires Nov 30, 2037